Passage Bio, Inc.

This early-stage study is testing a one-time gene therapy injection for adults with specific genetic forms of frontotemporal dementia (FTD). The treatment, called PBFT02, aims to deliver a working copy of a missing or faulty gene directly to the brain to potentially slow disease …